The Mayo Clinic Cancer Center (MCCC) provides oversight for the scientific aspects and performance of cancer interventional clinical trials conducted at Mayo Clinic through the Center's Protocol Review and Monitoring System (PRMS). The focus of the PRMS is on scientific merit, priorities, and progress of the clinical research protocols conducted at the MCCC. The Scientific Review Committee (SRC) uses a consistent and defined process for scientific review that is achieved through established written review criteria, common reporting forms, and defined expectations. The SRC has responsibility for the approval and/or disapproval of each study, as well as for the final decision concerning prioritization. To accommodate the increasing complexity and volume of trials, 4 SRC subcommittees cover trials in hematology and solid tumors with drug- predominant therapy, radiation-predominant therapy, and surgery-predominant therapy, respectively. Another subcommittee of the SRC, the Scientific Progress Review Subcommittee (SPRC), reviews modifications and amendments for approved and active studies. If the modification or amendment proposes significant changes to the scientific components of a trial, SPRC may request that the SRC review the change and determine if it is appropriate for the trial to remain active and for the modification or amendment to be implemented. SPRC also monitors accrual to interventional trials to ensure adequate scientific progress. If accrual is not adequate, SPRC will initially work with the investigator to determine the reasons. If progress is not made and there is no reasonable expectation that changes will occur, SPRC forwards the study to SRC for consideration of closure. The MCCC PRMS is under the governance of the MCCC Clinical Research Committee, which is chaired by the Deputy Director for Clinical Research. The Clinical Research Committee reviews and approves the leadership and membership of each SRC subcommittee at least annually. It also provides guidance on standard scientific review and administrative processes for SRC and SPRC and reviews the metrics from these committees quarterly.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547
DuBois, Steven G; Mosse, Yael P; Fox, Elizabeth et al. (2018) Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res 24:6142-6149
Farber, Benjamin A; Lalazar, Gadi; Simon, Elana P et al. (2018) Non coding RNA analysis in fibrolamellar hepatocellular carcinoma. Oncotarget 9:10211-10227

Showing the most recent 10 out of 1129 publications